|
RNF6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.28590000003648E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.79817000000027E-05 |
| Normal-vs-Stage2 |
3.488100E-02 |
| Normal-vs-Stage3 |
5.36329999967222E-07 |
| Normal-vs-Stage4 |
6.94699999748138E-08 |
| Stage1-vs-Stage2 |
4.230200E-01 |
| Stage1-vs-Stage3 |
9.328000E-02 |
| Stage1-vs-Stage4 |
2.225700E-02 |
| Stage2-vs-Stage3 |
9.965700E-02 |
| Stage2-vs-Stage4 |
2.756100E-02 |
| Stage3-vs-Stage4 |
3.759600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.70700000023949E-07 |
| Normal-vs-AfricanAmerican |
1.040360E-02 |
| Normal-vs-Asian |
4.356500E-04 |
| Caucasian-vs-AfricanAmerican |
4.531800E-01 |
| Caucasian-vs-Asian |
6.353400E-01 |
| AfricanAmerican-vs-Asian |
7.343800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.04070000009438E-07 |
| Normal-vs-Female |
2.00119999999027E-05 |
| Male-vs-Female |
9.757900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.27929999999854E-05 |
| Normal-vs-Age(41-60Yrs) |
3.19559999995001E-06 |
| Normal-vs-Age(61-80Yrs) |
3.94739999998173E-06 |
| Normal-vs-Age(81-100Yrs) |
8.602700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.191000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.344600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.876400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.280600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.199200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.266000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.882000E-01 |
| Classical-VS-Follicular |
3.997800E-01 |
| Classical-VS-Other |
1.952620E-01 |
| Classical-VS-Normal |
3.46179999999308E-06 |
| Tall-VS-Follicular |
1.282180E-01 |
| Tall-VS-Other |
4.499400E-01 |
| Tall-VS-Normal |
1.012510E-04 |
| Follicular-VS-Other |
2.043800E-01 |
| Follicular-VS-Normal |
4.258100E-03 |
| Other-VS-Normal |
3.157700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.35749999999424E-05 |
| Normal-vs-N1 |
3.05240000053608E-07 |
| N0-vs-N1 |
1.067000E-01 |
|
|
